PGGT1B

Across TCGA pan-cancer cohorts, PGGT1B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PGGT1B data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PGGT1B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PGGT1B expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

GBM, LUAD, and PDAC are the cancer types where PGGT1B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.188	0.495	.015	12	view →
LUAD	OS	Median	All	0.909	0.973	.019	8	view →
PDAC	DFS	Quartile	II,III,IV	0.549	0.250	.011	6	view →
UCEC	OS	Tertile	All	1.000	0.901	.020	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PGGT1B–GBM (DFS)

Open the GBM breakdown →